Initial reference price: will be the subscription price that will be published in the financial on or around 7 July 2006. Thresholds of listing: As provided in the ETA Nr 2004-433 dated 20 September 2002, the static price range will be set at +/-20% around the reference price. If the price is outside the static price range the stock will be reserved during 15 minutes. The new reference price used will be the treshold (up or down) reached previously. The static price range will be set at +/-10% of this new reference price. This procedure will be repeated until an opening price will be established. At the opening of the security, the opening price will be the new reference price with a static price range of +/-10% and a dynamic price range of +/-5%. Usual trading rules in term of thresholds and of reservation period will be applied. When Issued: according to the terms of the offering described in the prospectus, investors have to be aware that the offered shares must be delivered on 11 July 2006. Euronext Brussels has indicated that it will cancel all transactions realized on the regulated market Eurolist by Euronext Brussels if the offered shares are not delivered on 11 July 2006. The attention of the public is drawn upon the fact that, from the first listing of the shares on the regulated market Eurolist by Euronext Brussels and until 11 July 2006, it has to take into account the eventuality as described above for every operation that it intends to realise through Euronext or over the counter.
Listing on the Continuous Market - Group A1 - Compartment C
- A maximum of EUR 35 million new shares with VVPR-strip, which can be increased with a maximum amount of EUR 10 million up to an amount of EUR 45 million in case of a substantial oversubscription, qualifying for dividend as from 01.06.2006, that are offered in public subscription as from 22 June 2006 till 5 July 2006 included, unless closed in advance.
These shares will be mentioned in the price list under the name ThromboGenics with the mention WI until 11 July 2006 included (When Issued: cf infra).
- 14,362,527 existing shares of the company ThromboGenics.
- on a later to be determinated date: a maximum of 1,897,655 new shares coming from the possible exercise of warrants offered by ThromboGenics Ltd within the framework of the warrantplans.
N.B.: Until delivery of the physical shares, the settlement will only take place in a book-entry form through Euroclear Belgium (Transfer between accounts).